Antifibrotic agents targeting TGF-β signaling, including pirfenidone and nintedanib, have shown efficacy in pulmonary fibrosis and are being evaluated for cutaneous fibrosis [187]. This evidence concerns the gene TGFB1 and pulmonary fibrosis.